Four key genes, including IFIT2, IFIT3, RSAD2 and PARP14 were identified as potentially significant therapeutic targets, as well as indicators for SSc-PAH diagnosis and initiation of specific therapy. This evidence concerns the gene PARP14 and pulmonary arterial hypertension.